DDInter1702 DDInter704
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Sorafenib {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Everolimus
Sorafenib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Sorafenib {u} (Compound) downregulates {v} (Gene) INSIG1
INSIG1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Sorafenib {u} (Compound) upregulates {v} (Gene) GADD45B
GADD45B {u} (Gene) is upregulated by {v} (Compound) Everolimus
Sorafenib {u} (Compound) binds {v} (Gene) STK10
STK10 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Sorafenib {u} (Compound) upregulates {v} (Gene) NIPSNAP1
NIPSNAP1 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Sorafenib {u} (Compound) downregulates {v} (Gene) TFDP1
TFDP1 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Sorafenib {u} (Compound) causes {v} (Side Effect) Gastritis
Gastritis {u} (Side Effect) is caused by {v} (Compound) Everolimus
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Sorafenib (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is treated by Everolimus (Compound)
Sorafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Sorafenib (Compound) downregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Everolimus (Compound)
Sorafenib (Compound) upregulates GADD45B (Gene) and GADD45B (Gene) is upregulated by Everolimus (Compound)
Sorafenib (Compound) binds STK10 (Gene) and STK10 (Gene) is upregulated by Everolimus (Compound)
Sorafenib (Compound) upregulates NIPSNAP1 (Gene) and NIPSNAP1 (Gene) is downregulated by Everolimus (Compound)
Sorafenib (Compound) downregulates TFDP1 (Gene) and TFDP1 (Gene) is downregulated by Everolimus (Compound)
Sorafenib (Compound) causes Gastritis (Side Effect) and Gastritis (Side Effect) is caused by Everolimus (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)